We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+0.34%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.02B
AUM Growth
-$106M
Cap. Flow
-$45.5M
Cap. Flow %
-2.25%
Top 10 Hldgs %
46.17%
Holding
96
New
10
Increased
23
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$24.5M
2
AMGN icon
Amgen
AMGN
+$23.8M
3
SYK icon
Stryker
SYK
+$20.1M
4
JNJ icon
Johnson & Johnson
JNJ
+$19.2M
5
BSX icon
Boston Scientific
BSX
+$12.8M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$41.2M
2
ZBH icon
Zimmer Biomet
ZBH
+$39.6M
3
AVTR icon
Avantor
AVTR
+$34.3M
4
VEEV icon
Veeva Systems
VEEV
+$27.5M
5
WST icon
West Pharmaceutical
WST
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGN icon
76
Align Technology
ALGN
$12.1B
– –
-22,751
Closed -$7.46M
ARKK icon
77
ARK Innovation ETF
ARKK
$5.66B
– –
-242,260
Closed -$12.1M
ATXS
78
DELISTED
Astria Therapeutics
ATXS
– –
-327,045
Closed -$4.6M
AVTR icon
79
Avantor
AVTR
$9.32B
– –
-1,343,309
Closed -$34.3M
BLUE
80
DELISTED
bluebird bio
BLUE
– –
-102,133
Closed -$2.61M
FXI icon
81
CALL
iShares China Large-Cap ETF
FXI
$4.35B
– –
-1,022,800
Closed -$24.6M
FXI icon
82
iShares China Large-Cap ETF
FXI
$4.35B
– –
-141,122
Closed -$3.4M
HCA icon
83
CALL
HCA Healthcare
HCA
$87.2B
– –
-71,800
Closed -$23.9M
INSP icon
84
Inspire Medical Systems
INSP
$1.45B
– –
-33,557
Closed -$7.21M
IWM icon
85
CALL
iShares Russell 2000 ETF
IWM
$80.2B
– –
-88,600
Closed -$18.6M
IWM icon
86
iShares Russell 2000 ETF
IWM
$80.2B
– –
-99,115
Closed -$20M
LEGN icon
87
Legend Biotech
LEGN
$3.59B
– –
-734,293
Closed -$41.2M
TLT icon
88
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$41.4B
– –
-523,000
Closed -$49.5M
VEEV icon
89
Veeva Systems
VEEV
$33.1B
– –
-118,905
Closed -$27.5M
WST icon
90
West Pharmaceutical
WST
$24B
– –
-51,197
Closed -$20.3M
ZBH icon
91
Zimmer Biomet
ZBH
$18.2B
– –
-300,351
Closed -$39.6M
SILK
92
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-331,064
Closed -$6.07M
INBX
93
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-47,918
Closed -$1.68M
1 2 3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q2 2024 Portfolio in Review

As of Q2 2024, PFM Health Sciences held 96 positions worth $2.02B, down 5% from $2.13B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

PFM Health Sciences's Q2 2024 filing shows 10 new, 23 increased, 12 reduced and 18 closed positions. Its largest new stake was Amgen: 81,034 shares worth $25.3M. The largest sale was Legend Biotech, an estimated $41.2M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

  • PFM Health Sciences's largest Q2 2024 buy was Amgen: 81,034 shares worth $25.3M.
  • PFM Health Sciences added most to UnitedHealth in Q2 2024, an estimated $24.5M increase.
  • PFM Health Sciences's biggest Q2 2024 reduction was Becton Dickinson, cutting an estimated $9.46M.
  • PFM Health Sciences fully exited Legend Biotech in Q2 2024, selling an estimated $41.2M.
  • PFM Health Sciences's ten largest holdings make up 46% of its $2.02B portfolio in Q2 2024.
  • PFM Health Sciences opened 10 new positions and closed 18 in Q2 2024.
  • PFM Health Sciences's portfolio value fell 5% quarter-over-quarter to $2.02B.

Based on PFM Health Sciences's 13F filing for Q2 2024, filed 14 Aug 2024.